High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer

Research output: Contribution to journalJournal articlepeer-review

  • Mads Heilskov Rasmussen
  • Niels Frank Jensen
  • Line Schmidt Tarpgaard
  • Camilla Qvortrup
  • Maria Unni Koefoed Rømer
  • Stenvang, Jan
  • Tine Plato Hansen
  • Lise Lotte Christensen
  • Jan Lindebjerg
  • Flemming Hansen
  • Benny V. Jensen
  • Torben F. Hansen
  • Per Pfeiffer
  • Nils Brünner
  • Torben Falck Ørntoft
  • Claus Lindbjerg Andersen
The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of approximately 50% for either treatment combination, a major unsolved problem is that no predictors of response to these treatments are available. To address this issue, we profiled 742 microRNAs in laser-capture microdissected cancer cells from responding and non-responding patients receiving XELOX/FOLFOX as first-line treatment for mCRC, and identified, among others, high expression of miR-625-3p, miR-181b and miR-27b to be associated with poor clinical response. In a validation cohort of 94 mCRC patients treated first-line with XELOX, high expression of miR-625-3p was confirmed to be associated with poor response (OR = 6.25, 95%CI [1.8; 21.0]). Independent analyses showed that miR-625-3p was not dysregulated between normal and cancer samples, nor was its expression associated with recurrence of stage II or III disease, indicating that miR-625-3p solely is a response marker. Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells. Altogether, our results suggest an association between miR-625-3p and response to first-line oxaliplatin based chemotherapy of mCRC.
Original languageEnglish
JournalMolecular Oncology
Volume7
Issue number3
Pages (from-to)637-646
Number of pages10
ISSN1574-7891
DOIs
Publication statusPublished - 2013

ID: 59298979